Organon & Co. (NYSE:OGN) Stock Position Lifted by Victory Capital Management Inc.

Victory Capital Management Inc. grew its holdings in Organon & Co. (NYSE:OGN) by 127.3% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 183,298 shares of the company’s stock after acquiring an additional 102,663 shares during the period. Victory Capital Management Inc. owned 0.07% of Organon & Co. worth $3,506,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the business. Verus Capital Partners LLC grew its position in Organon & Co. by 65.4% in the third quarter. Verus Capital Partners LLC now owns 39,193 shares of the company’s stock worth $750,000 after acquiring an additional 15,501 shares in the last quarter. Versor Investments LP lifted its stake in shares of Organon & Co. by 47.0% in the third quarter. Versor Investments LP now owns 47,026 shares of the company’s stock worth $900,000 after buying an additional 15,026 shares during the last quarter. Los Angeles Capital Management LLC lifted its stake in shares of Organon & Co. by 47.4% in the third quarter. Los Angeles Capital Management LLC now owns 259,831 shares of the company’s stock worth $4,971,000 after buying an additional 83,510 shares during the last quarter. River Global Investors LLP lifted its stake in shares of Organon & Co. by 4.8% in the third quarter. River Global Investors LLP now owns 58,775 shares of the company’s stock worth $1,124,000 after buying an additional 2,711 shares during the last quarter. Finally, Crossmark Global Holdings Inc. lifted its stake in shares of Organon & Co. by 43.4% in the third quarter. Crossmark Global Holdings Inc. now owns 20,157 shares of the company’s stock worth $385,000 after buying an additional 6,096 shares during the last quarter. 77.43% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the stock. Evercore ISI upgraded shares of Organon & Co. to a “strong-buy” rating in a research note on Wednesday, September 18th. JPMorgan Chase & Co. cut shares of Organon & Co. from a “neutral” rating to an “underweight” rating and boosted their price objective for the stock from $18.00 to $20.00 in a research note on Friday, September 6th.

Organon & Co. Price Performance

NYSE:OGN opened at $15.28 on Friday. The stock has a market cap of $3.94 billion, a P/E ratio of 3.03, a PEG ratio of 0.70 and a beta of 0.84. Organon & Co. has a one year low of $10.84 and a one year high of $23.10. The company has a fifty day moving average price of $17.61 and a 200 day moving average price of $19.77. The company has a debt-to-equity ratio of 17.73, a current ratio of 1.70 and a quick ratio of 1.21.

Organon & Co. (NYSE:OGN) last released its earnings results on Thursday, October 31st. The company reported $0.87 EPS for the quarter, missing the consensus estimate of $0.90 by ($0.03). The company had revenue of $1.58 billion for the quarter, compared to analyst estimates of $1.56 billion. Organon & Co. had a net margin of 20.30% and a return on equity of 644.70%. Organon & Co.’s revenue for the quarter was up 4.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.78 earnings per share. Analysts anticipate that Organon & Co. will post 3.89 earnings per share for the current year.

Organon & Co. Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, December 12th. Investors of record on Tuesday, November 12th will be paid a dividend of $0.28 per share. This represents a $1.12 annualized dividend and a yield of 7.33%. The ex-dividend date of this dividend is Tuesday, November 12th. Organon & Co.’s payout ratio is currently 22.22%.

About Organon & Co.

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.